Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 10/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 5/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GGPS1 | O95749 | 6/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55151 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL16970225 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL349512 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL16969619 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL16180459 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL2833675 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL16970217 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL16969980 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL665460 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 | |
| SCHEMBL11370224 | 0.87 | TSHR (0.50) | TSHRTHRBFDPSSMPD1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1124828-B1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LAB (US) | 2008-01-02 | — | — | EP | disclosed |
| US-6642222-B2 | Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions | ABBOTT LABORATORIES | 2003-11-04 | — | — | US | disclosed |
| US-6632418-B2 | Therapy for asthma, sexual disorders, hypotensive agents, analgesics | ABBOTT LABORATORIES | 2003-10-14 | — | — | US | disclosed |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | ABBOTT LABORATORIES | 2003-04-03 | — | — | US | disclosed |
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | ABBOTT LABORATORIES | 2003-03-20 | — | — | US | disclosed |
| WO-2003011869-A1 | RADIOLIGANDS AND THEIR USE FOR IDENTIFYING POTASSIUM CHANNEL MODULATORS | ABBOTT LABORATORIES (US) | 2003-02-13 | — | — | WO | disclosed |
| EP-1124828-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2001-08-22 | — | — | EP | disclosed |
| US-6191140-B1 | POTASSIUM CHANNEL MODULATORS; MUSCLE RELAXANTS; CONTROLLING CELL MEMBRANES | ABBOTT LABORATORIES | 2001-02-20 | — | — | US | disclosed |
| EP-0482208-B1 | PYRIDAZINONE DERIVATIVE | NISSAN CHEMICAL IND LTD (JP) | 2000-07-19 | — | — | EP | disclosed |
| WO-2000024743-A1 | PYRANO, PIPERIDINO, AND THIOPYRANO COMPOUNDS AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2000-05-04 | — | — | WO | disclosed |
| US-5318968-A | Antithrombotic agents; cardiotonic agents; vasodilators | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| US-5314883-A | Vasodilation, anticoagulants | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-05-24 | — | — | US | disclosed |
| US-5202323-A | Antithrombotic, inotropic, vasodilator, antiallergen | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-04-13 | — | — | US | disclosed |
| EP-0482208-A1 | PYRIDAZINONE DERIVATIVE | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055035-A1 | Pyrano piperidino and thiopyrano compounds and methods of use | KCNJ3, KCNJ6, KCNJ5 | TSHR 2656/4885THRB 1709/4885FDPS 1413/4885 |
| US-20030065182-A1 | Novel radioligands and their use for identifying potassium channel modulators | KCNN3, KCNN1, KCNN2 | TSHR 467/4885THRB 421/4885FDPS 3191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.